EC Number   |
Inhibitors |
Structure |
|---|
   3.4.24.18 | 1,10-phenanthroline |
- |
   |
| 3.4.24.18 | 1,10-phenanthroline |
at neutral and alkaline pH-values, reversible by dialysis |
|
| 3.4.24.18 | 2-(N-Hydroxycarboxamido)-4-methylpentanoyl-L-alanyl-glycylamide |
i.e. Zinkov inhibitor |
|
| 3.4.24.18 | 2-mercaptoethanol |
- |
|
| 3.4.24.18 | 3-[(E)-[4-formyl-5-hydroxy-6-methyl-3-[(phosphonooxy)methyl]pyridin-2-yl]diazenyl]-7-nitronaphthalene-1,5-disulfonic acid |
competitive inhibition |
|
| 3.4.24.18 | Acetyl-Arg-Pro-Gly-Tyr hydroxamate |
kinetics |
|
| 3.4.24.18 | actinonin |
i.e. 3-[[1-[[2-(hydroxymethyl)-1-pyrolidinyl]carbonyl]-2-methylpropyl]carbamoyl]octano hydroxamic acid, strong, kinetics |
|
| 3.4.24.18 | actinonin |
- |
|
| 3.4.24.18 | actinonin |
in a mouse model of sepsis induced by cecal ligation puncture that results in elevated levels of serum interleukin 1beta, meprin inhibitor actinonin significantly reduces levels of serum interleukin 1beta |
|
| 3.4.24.18 | actinonin |
pre-ischemic treatment with actinonin at 10 or 30 mg/kg, i.v. dose-ependently attenuates the ischemia/reperfusion-induced renal injury in male rats, but fails to improve the renal injury in female rats |
|
